As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above